Japan's Ministry of Health, Labour and Welfare has approved the extension of the present marketing authorisation for United States-based Alexion Pharmaceuticals' SOLIRIS to include the prevention of relapse in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica, it was reported yesterday.
The SOLIRIS approval was based on comprehensive results from the Phase three randomised, double-blind placebo controlled PREVENT trial, which were published in The New England Journal of Medicine and a long-term extension study (ECU-NMO-302), which is still underway.
The product was approved for the treatment of NMOSD in adult patients who are anti-AQP4 antibody-positive by the United States Food and Drug Administration (FDA) in June 2019 and by the European Commission (EC) in August 2019. The product received Orphan Drug Designation for the treatment of NMOSD in the US, EU and Japan.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study